Established in 1995, Hansoh Pharm has grown into a new pharmaceutical group featuring R&D, manufacture, sales and pharmaceutical investment of drugs. In 2011, over 4500 employees bring Hansoh total revenue of 640 million US dollars. Hansoh has 76 products which cover 6 therapeutic categories: anticancer, antibiotic, psychotropic, anti-diabetic, gastro-intestinal and cardiovascular area. We are also making efforts to the research on the new products. While achieving great success in domestic market, through direct and active participation, Hansoh is gaining steadily in global market. Several APIs have been exported to North America, Europe, Africa and Asia. Vinorelbine and Gemcitabine have occupied over 23% of the global market. Over 30 foreign pharmaceutical companies are sourcing our products. Backed by strong R&D teams, Hansoh continues to be at the forefront of the life-science industry of China. Each year, Hansoh spends more than 8% of the revenue on R&D. Till now, Hansoh has filed more than 120 intellectual properties and 19 of them have been granted. Always flexible and dynamic, Hansoh’s production capacity grows very rapidly. In 2007, a new world-class API manufacturing site — DAPU SITE was built. In 2011, new finished products manufacturing site has been completed. With continuous improvement, Hansoh’s quality system complies with the strictest regulatory requirements of leading health authorities. It has been inspected and approved by US FDA, Japan PMDA, Korea KFDA, etc. Hansoh can provide USP, EP and JP standard products to different customers all over the world. We are looking forward to promoting great cooperative relationships with customers from all over the world. And we believe that Hansoh Pharm must be a best API supplier of your company. JIANGSU HANSOH PHARMACEUTICAL CO. LTD. No.9, Dongjin Road, Economic & Technical Development Zone, Lianyungang, Jiangsu, 222069, China T/86-0518-83096066 F/86-0518-83099500 http://www.hansoh.cn